Opinion|Videos|April 18, 2025
Closing Insights: The Future of Cemiplimab in NSCLC and Beyond
Author(s)Eric K. Singhi, M.D., Ben Creelan, M.D.
Panelists discuss how, as new data on cemiplimab and other checkpoint inhibitors emerge, the treatment pathway for cancers like non-small cell lung cancer (NSCLC) is expected to evolve toward more personalized, targeted approaches. This will enhance survival outcomes, refine patient selection and optimize therapy regimens.
Advertisement
Episodes in this series
Video content above is prompted by the following:
- As new data on cemiplimab and other checkpoint inhibitors continue to emerge, how do you anticipate the overall treatment pathway for cancers like NSCLC will change?
Advertisement
Related to this article
AI pathology tool measures lung cancer treatment response after neoadjuvant chemoimmunotherapy with 91% accuracy, speeding NSCLC care while needing review for complete response.
Rybrevant (amivantamab) plus chemotherapy reached a 34.3-month median survival in EGFR exon 20 insertion-positive lung cancer, Johnson & Johnson said.
Advertisement
Advertisement
Trending on Managed Healthcare Executive
1
National Alliance names interim head after arrest of its president
2
Biosimilars are reshaping pricing and drug development — the numbers behind it
3
Community oncologists are turning to AI, but not all of them use predictive models
4
CMS should test behavior-informed approaches to chronic care
5